Vericel Croissance future
Future contrôle des critères 4/6
Vericel devrait augmenter ses bénéfices et ses revenus de 32.4% et de 14.9% par an respectivement, tandis que le BPA devrait croître de croître de 30.9% par an.
Informations clés
32.4%
Taux de croissance des bénéfices
30.92%
Taux de croissance du BPA
| Biotechs croissance des bénéfices | 27.6% |
| Taux de croissance des recettes | 14.9% |
| Rendement futur des capitaux propres | n/a |
| Couverture par les analystes | Good |
| Dernière mise à jour | 03 Aug 2026 |
Mises à jour récentes de la croissance future
Recent updates
Mise à jour du récit • Jul 31
VCEL: Raised Guidance And Buyback Will Support Stronger Forward Repricing
Analysts have raised their fair value estimate for Vericel stock from $42.00 to $55.00, citing recent price target increases that follow reported MACI performance in Q2, as well as guidance they consider achievable for the second half of the year. Analyst Commentary Recent Street research on Vericel has focused on how current expectations for MACI and the broader MedTech backdrop feed into risk and reward for the stock.
Mise à jour du récit • Jul 17
VCEL: Raised Outlook And New Headquarters Will Support Stronger Future Position
Vericel's implied fair value estimate has moved from about $53.88 to $57.14 as analysts adjust their price targets, citing updated expectations around revenue growth, profit margins and sector volatility. What’s in the News for Vericel Vericel approved an amendment to the company’s bylaws to reflect the relocation of its principal executive offices to a new global headquarters at 25 Blue Sky Drive, Burlington, Massachusetts 01803.
Mise à jour du récit • Jun 26
VCEL: Strong Q1 Execution And BARDA Contract Will Drive Future Upside
Analysts have raised their fair value estimate for Vericel to $70.00 from $64.00, citing updated assumptions on revenue growth, profit margins, and future P/E, even as some Street targets such as Truist's have recently moved lower. What’s in the News for Vericel Analysts highlighted Vericel’s recent first quarter results, where revenues were reported at 7.6% above expectations and statutory losses were reduced, according to a summary of Wall Street research (source: Zacks / TD Cowen coverage summary).Article d’analyse • Jun 22
Vericel (VCEL) Stock Could Be 37.3% Undervalued After Earnings Beat And Fund Buying
Vericel (VCEL) has drawn fresh attention after institutional holders such as BlackRock and State Street lifted their positions, and the company reported quarterly earnings per share that came in above market expectations. See our latest analysis for Vericel. Vericel's share price has picked up momentum recently, with a 1-day share price return of 2.48%, 7-day return of 7.05%, and 90-day return of 23.57%. This comes even though the 1-year total shareholder return declined 4.57% and the 5-year...Article d’analyse • May 09
The Vericel Corporation (NASDAQ:VCEL) First-Quarter Results Are Out And Analysts Have Published New Forecasts
As you might know, Vericel Corporation ( NASDAQ:VCEL ) just kicked off its latest quarterly results with some very...Nouveau récit • May 02
Expanded Cell Therapy Capacity And Burn Care Franchise Will Drive Multiyear Upside Potential
Catalysts About Vericel Vericel develops and manufactures advanced cell therapies for cartilage repair and severe burn care. What are the underlying business or industry changes driving this perspective?Nouveau récit • Apr 17
Expanded Cell Therapy Pipeline Will Face Execution Risks Yet Ultimately Support Healthier Business
Catalysts About Vericel Vericel develops and manufactures advanced cell therapies for sports medicine and burn care, including MACI for cartilage repair and Epicel and NexoBrid in burn care. What are the underlying business or industry changes driving this perspective?Seeking Alpha • Jan 04
Vericel: Growth Plans May Have Run Out Of Gas (Rating Downgrade)
Summary Vericel (VCEL) is rated a hold due to inconsistent growth, fluctuating profitability, and limited near-term upside at current valuation. VCEL’s future hinges on scaling MACI, as Epicel and Nexobrid have stalled and face capped demand in niche markets. International expansion and MACI Arthro could drive growth, but execution risks and delayed timelines temper confidence in acceleration. Despite strong cash and no long-term debt, persistent SG&A growth and negative free cash flow highlight challenges in achieving sustainable profitability. Read the full article on Seeking AlphaArticle d’analyse • Nov 12
There's No Escaping Vericel Corporation's (NASDAQ:VCEL) Muted Revenues Despite A 29% Share Price Rise
Vericel Corporation ( NASDAQ:VCEL ) shares have had a really impressive month, gaining 29% after a shaky period...Article d’analyse • Jun 16
Does Vericel (NASDAQ:VCEL) Deserve A Spot On Your Watchlist?
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...Article d’analyse • May 01
Risks To Shareholder Returns Are Elevated At These Prices For Vericel Corporation (NASDAQ:VCEL)
With a median price-to-sales (or "P/S") ratio of close to 9.6x in the Biotechs industry in the United States, you could...Seeking Alpha • Mar 06
Vericel: Scalable Growth With Strong Margins
Summary Vericel's niche in regenerative medicine is undervalued, with FDA-approved products like MACI, Epicel, and NexoBrid driving steady revenue growth and profitability. The company's strong financials include $167 million in cash, zero debt, and a 16% year-over-year revenue increase, highlighting operational efficiency. MACI's expansion into ankle cartilage repair and a robust pipeline suggest significant future earnings potential, despite current market hesitations. VCEL's strategy focuses on indication expansion and market penetration, aiming for long-term margin growth and reduced vulnerability to high-risk drug development. Read the full article on Seeking AlphaSeeking Alpha • Dec 19
Vericel Corporation: Hard To Justify Current Valuation
Summary Vericel Corporation, specializing in cellular therapies for sports medicine and severe burn care, has seen a 40% rise in its stock recently. Core products include MACI, NexoBrid, and Epicel, with Q3 revenues rising 27% year-over-year to $57.9 million, beating expectations. The company is turning the corner on profitability, but valuations look stretched at current trading levels. An analysis around Vericel follows in the paragraphs below. Read the full article on Seeking AlphaArticle d’analyse • Nov 09
Vericel Corporation (NASDAQ:VCEL) Stock Rockets 32% As Investors Are Less Pessimistic Than Expected
Vericel Corporation ( NASDAQ:VCEL ) shares have had a really impressive month, gaining 32% after a shaky period...
Nouveau récit • Sep 10
MACI And NexoBrid Drive Record Revenues And Profit Growth, Setting Stage For Robust Future Performance
Expansion of MACI and NexoBrid markets driving record revenues, indicating significant future revenue growth.Article d’analyse • Jul 12
What Vericel Corporation's (NASDAQ:VCEL) P/S Is Not Telling You
With a median price-to-sales (or "P/S") ratio of close to 11.3x in the Biotechs industry in the United States, you...Article d’analyse • May 11
Vericel Corporation (NASDAQ:VCEL) First-Quarter Results: Here's What Analysts Are Forecasting For This Year
Vericel Corporation ( NASDAQ:VCEL ) just released its first-quarter report and things are looking bullish. Revenues and...Article d’analyse • Apr 26
It's Unlikely That The CEO Of Vericel Corporation (NASDAQ:VCEL) Will See A Huge Pay Rise This Year
Key Insights Vericel will host its Annual General Meeting on 1st of May Salary of US$790.0k is part of CEO Nick...Article d’analyse • Mar 02
Is There An Opportunity With Vericel Corporation's (NASDAQ:VCEL) 49% Undervaluation?
Key Insights Using the 2 Stage Free Cash Flow to Equity, Vericel fair value estimate is US$87.12 Vericel is estimated...Article d’analyse • Feb 02
Revenues Not Telling The Story For Vericel Corporation (NASDAQ:VCEL) After Shares Rise 29%
Vericel Corporation ( NASDAQ:VCEL ) shareholders would be excited to see that the share price has had a great month...Article d’analyse • May 05
Vericel Corporation's (NASDAQ:VCEL) Shareholders Might Be Looking For Exit
It's not a stretch to say that Vericel Corporation's ( NASDAQ:VCEL ) price-to-sales (or "P/S") ratio of 9.4x right now...Prévisions de croissance des bénéfices et des revenus
| Date | Recettes | Les revenus | Flux de trésorerie disponible | Cash from Op | Moy. Nombre d'analystes |
|---|---|---|---|---|---|
| 12/31/2028 | 455 | 73 | N/A | N/A | 7 |
| 12/31/2027 | 393 | 47 | N/A | N/A | 8 |
| 12/31/2026 | 336 | 29 | N/A | 98 | 8 |
| 6/30/2026 | 306 | 24 | 62 | 70 | N/A |
| 3/31/2026 | 292 | 21 | 47 | 62 | N/A |
| 12/31/2025 | 276 | 17 | 25 | 52 | N/A |
| 9/30/2025 | 259 | 13 | 20 | 59 | N/A |
| 6/30/2025 | 249 | 7 | -8 | 47 | N/A |
| 3/31/2025 | 239 | 3 | -7 | 58 | N/A |
| 12/31/2024 | 237 | 10 | -6 | 58 | N/A |
| 9/30/2024 | 227 | 4 | -12 | 46 | N/A |
| 6/30/2024 | 215 | 1 | -2 | 43 | N/A |
| 3/31/2024 | 208 | 0 | 2 | 35 | N/A |
| 12/31/2023 | 198 | -3 | 8 | 35 | N/A |
| 9/30/2023 | 185 | -10 | 11 | 32 | N/A |
| 6/30/2023 | 178 | -13 | 13 | 29 | N/A |
| 3/31/2023 | 169 | -17 | 9 | 22 | N/A |
| 12/31/2022 | 164 | -17 | 10 | 18 | N/A |
| 9/30/2022 | 159 | -18 | 14 | 21 | N/A |
| 6/30/2022 | 155 | -16 | 12 | 21 | N/A |
| 3/31/2022 | 158 | -11 | 14 | 22 | N/A |
| 12/31/2021 | 156 | -7 | 21 | 29 | N/A |
| 9/30/2021 | 154 | 0 | 22 | 30 | N/A |
| 6/30/2021 | 152 | 9 | 25 | 31 | N/A |
| 3/31/2021 | 132 | 4 | 19 | 23 | N/A |
| 12/31/2020 | 124 | 3 | 15 | 18 | N/A |
| 9/30/2020 | 118 | 0 | 7 | 9 | N/A |
| 6/30/2020 | 117 | 0 | 10 | 13 | N/A |
| 3/31/2020 | 123 | -12 | N/A | -3 | N/A |
| 12/31/2019 | 118 | -10 | N/A | -7 | N/A |
| 9/30/2019 | 110 | -14 | N/A | -8 | N/A |
| 6/30/2019 | 102 | -18 | N/A | -14 | N/A |
| 3/31/2019 | 95 | -3 | N/A | -1 | N/A |
| 12/31/2018 | 91 | -8 | N/A | 0 | N/A |
| 9/30/2018 | 83 | -13 | N/A | -2 | N/A |
| 6/30/2018 | 75 | -17 | N/A | -9 | N/A |
| 3/31/2018 | 73 | -15 | N/A | -10 | N/A |
| 12/31/2017 | 64 | -17 | N/A | -13 | N/A |
| 9/30/2017 | 57 | -26 | N/A | -23 | N/A |
| 6/30/2017 | 54 | -29 | N/A | -22 | N/A |
| 3/31/2017 | 50 | -31 | N/A | -22 | N/A |
| 12/31/2016 | 54 | -27 | N/A | -20 | N/A |
| 9/30/2016 | 53 | -26 | N/A | -15 | N/A |
| 6/30/2016 | 54 | -23 | N/A | -11 | N/A |
| 3/31/2016 | 54 | -22 | N/A | -11 | N/A |
| 12/31/2015 | 51 | -23 | N/A | -13 | N/A |
| 9/30/2015 | 50 | -20 | N/A | -16 | N/A |
Prévisions de croissance des analystes
Taux de revenus par rapport au taux d'épargne: La croissance des bénéfices prévue de VCEL ( 32.4% par an) est supérieure au taux d'épargne ( 3.7% ).
Bénéfices vs marché: Les bénéfices de VCEL ( 32.4% par an) devraient croître plus rapidement que le marché US ( 16.8% par an).
Croissance élevée des bénéfices: Les bénéfices de VCEL devraient augmenter de manière significative au cours des 3 prochaines années.
Chiffre d'affaires vs marché: Le chiffre d'affaires de VCEL ( 14.9% par an) devrait croître plus rapidement que le marché US ( 12.9% par an).
Croissance élevée des revenus: Le chiffre d'affaires de VCEL ( 14.9% par an) devrait croître plus lentement que 20% par an.
Prévisions de croissance du bénéfice par action
Rendement futur des capitaux propres
ROE futur: Données insuffisantes pour déterminer si le retour sur capitaux propres de VCEL devrait être élevé dans 3 ans
Découvrir les entreprises en croissance
Analyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/08/10 04:26 |
| Cours de l'action en fin de journée | 2026/08/10 00:00 |
| Les revenus | 2026/06/30 |
| Revenus annuels | 2025/12/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github ; nous proposons également des guides sur la façon d’utiliser nos rapports et des tutoriels sur YouTube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
Vericel Corporation est couverte par 20 analystes. 8 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| Keay Nakae | Ascendiant Capital Markets LLC |
| Michael Gorman | BTIG |
| Caitlin Cronin | Canaccord Genuity |